Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer by Cobham, Marta Vallee & Donovan, Diana
© 2009 Cobham and Donovan, publisher and licensee Dove Medical Press Ltd. This is an Open Access article   
which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2009:1 69–77
Cancer Management and Research
69
R e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
ixabepilone: a new treatment option 
for the management of taxane-resistant 
metastatic breast cancer
Marta vallee Cobham 
Diana Donovan
weill Cornell Breast Center, Cornell 
University/New York-Presbyterian 
Hospital, New York, NY, USA
Correspondence: Marta v Cobham 
Division of Hematology/Oncology, 
weill Cornell Breast Center Cornell 
University/New York-Presbyterian 
Hospital, 425 east 61st St, 8th Floor 
New York, NY 10021 USA 
Tel +1 212-821-0780 
Fax +1 212-821-0758 
email mac2034@med.cornell.edu
Abstract: Ixabepilone (Ixempra®; Bristol-Myers Squibb) is a novel microtubule stabilizing 
agent recently approved for the treatment of metastatic breast cancer (MBC). This article focuses 
on considerations for ixabepilone administration and adverse event (AE) management, draw-
ing from the biomedical literature indexed in PubMed, published abstracts from the American 
Society of Clinical Oncology annual meetings, and the manufacturer’s prescribing information 
for ixabepilone. Administered as monotherapy or in combination with capecitabine in clinical 
studies, ixabepilone demonstrated positive clinical response rates, prolonged progression-free 
survival, and a favorable safety profile in patients with MBC. Treatment-related AEs were pre-
dictable and manageable with dose modification, treatment interruption, and active management. 
As ixabepilone undergoes development in earlier lines of breast cancer therapy and in other solid 
tumors, oncology nurses will encounter more and more patients receiving ixabepilone therapy. 
If nurses are acquainted with the unique management strategies associated with ixabepilone 
treatment, as detailed herein, patients are more likely to receive the full benefit of therapy.
Keywords: breast cancer, chemotherapy, microtubule-stabilizing agent, ixabepilone, adverse 
events, patient management
Breast cancer is the most frequently diagnosed cancer among women.1 It is estimated 
that in 2008, more than 182,000 women in the United States were diagnosed with 
breast cancer and more than 40,000 died from the disease.2 At diagnosis, the majority 
of women (52% to 61%) have localized tumors; the remainder have tumors that have 
spread regionally (31% to 36%) or have distant metastases (6% to 9%).2 The 5-year 
survival rates are high for female breast cancer that is localized at diagnosis (98%), 
but rates are lower for breast cancer that is diagnosed at regional and distant invasive 
stages (approximately 84% and 27%, respectively).3
Metastatic breast cancer (MBC) is essentially incurable, and chemotherapy is 
commonly prescribed with the goals of maximizing patient quality of life, preventing 
and/or relieving symptoms, and prolonging survival.4 Unfortunately, resistance to com-
mon chemotherapeutic agents (eg, anthracyclines and taxanes) is a major cause of treat-
ment failure.5−7 Anthracycline and taxane use in the adjuvant and neoadjuvant settings is 
increasing the proportion of breast cancer patients who are resistant to these agents in the 
metastatic setting.8 Multidrug resistance (MDR), defined as a cross-resistance to structur-
ally unrelated compounds, is thought to occur through a variety of mechanisms, including 
alterations or mutations in apoptotic pathways or drug targets. Moreover, tumor cells 
frequently express higher-than-normal levels of drug efflux proteins, allowing the cells Cancer Management and Research 2009:1 70
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to reduce intracellular drug concentrations to nontoxic levels. 
A wide variety of cytotoxic and targeted anticancer agents are 
susceptible to this mechanism of drug resistance.9−11 Treatment 
resistance represents a significant challenge to healthcare 
professionals and their patients in the management of MBC.12 
Thus, development of improved cytotoxic agents that effec-
tively evade these resistance mechanisms is critical.
The epothilones, a novel class of antineoplastic 
microtubule-stabilizing agents (MSAs), provide a promising 
alternative to taxane therapy. Like the taxanes, epothilones 
stabilize microtubules by binding to the β-tubulin subunit 
of the α,β-tubulin heterodimer, which eventually induces 
tumor cell death.13,14 Importantly, however, the epothilones 
are structurally unrelated to the taxanes, and the two classes 
have different β-tubulin binding modes.15
Among the epothilones, ixabepilone (aza-epothilone B; 
Ixempra®; Bristol-Myers Squibb, Princeton, NJ, USA) is 
furthest along in clinical development. Ixabepilone pos-
sesses greater cytotoxic activity than taxanes in cell lines that 
overexpress drug efflux transporters (multidrug resistance-
associated protein [MRP]-1, P-glycoprotein [Pgp], or breast 
cancer resistance protein [BCRP]), as well as those that 
overexpress β-III tubulin, an isoform to which the taxanes 
cannot bind.10,16−18 Ixabepilone’s antitumor activity and lack 
of cross-resistance with the taxanes has led to its extensive 
clinical testing in a wide variety of solid tumor disease states, 
many of which are characterized by resistance to established 
agents such as taxanes and anthracyclines.
The objectives of this article are to provide practicing 
oncology team members with a summary of efficacy and 
tolerability data from three key ixabepilone clinical trials, a 
discussion of management strategies for common ixabepilone-
associated adverse events (AEs), and a review of ixabepilone 
dosing and administration procedures. In addition to references 
for these three key clinical trials, sections on adverse events 
drew from the US prescribing information for ixabepilone 
and the published body of literature available on the PubMed, 
American Society of Clinical Oncology, and San Antonio 
Breast Cancer Society websites. Subject-specific literature 
searches were conducted, and preference for inclusion in this 
article was given to references with recent, well-designed data 
that were applicable to clinical practice, at the authors’ discre-
tion based on their own extensive clinical experience.
Ixabepilone clinical data
Ixabepilone has demonstrated considerable efficacy in 
MBC patients, even in those who are heavily pretreated and 
whose lesions have progressed after treatment with multiple 
therapeutic agents. In October 2007, ixabepilone received 
US Food and Drug Administration (FDA) approval for the 
treatment of locally advanced or MBC after failure of an 
anthracycline and a taxane (in combination with capecitabine) 
and as monotherapy after failure of an anthracycline, a taxane, 
and capecitabine.17 This approval was based primarily on two 
large clinical trials, BMS Studies 081 and 046. Study 081 was 
a single-arm phase II trial evaluating the efficacy of ixabepilone 
monotherapy (40 mg/m2 intravenous [IV] over 3 hours every 
3 weeks) in 126 MBC patients whose disease had progressed 
on anthracycline, taxane, and capecitabine therapy.19 Study 046 
was a pivotal randomized phase III trial that evaluated the 
combination of ixabepilone (40 mg/m2 IV over 3 hours every 
3 weeks) and capecitabine (1000 mg/m2 orally twice daily for 
14 days of a 3-week cycle; n = 375) versus capecitabine alone 
(1250 mg/m2 orally twice daily for 14 days of a 3-week cycle; 
n = 377) in 752 patients with anthracycline- and taxane-resistant 
MBC (strictly defined as recurrence within 4 months of the last 
dose in the metastatic setting or within 12 months in the adju-
vant setting).20 Subsequently, a larger confirmatory trial (BMS 
Study 048) enrolled 1221 taxane- and anthracycline-pretreated 
MBC patients, 50% of whom met the resistance criteria 
defined in Study 046. Using the same treatment protocol as in 
Study 046, the 048 trial compared progression-free and overall 
survival for patients receiving ixabepilone and capecitabine 
doublet versus capecitabine monotherapy.21 Efficacy data from 
these three trials are summarized in Table 1.
These three trials utilized the recommended ixabepi-
lone dose of 40 mg/m2; the incidences of treatment-related 
AEs reported from Studies 046 and 081 are provided in 
Table 2.17 Serious AEs (grade 3 or 4) were by nature hema-
tologic (ie, myelosuppression), dermatologic (skin reactions 
and nail disorders), pain-related, and gastrointestinal. The 
trials evaluating the ixabepilone/capecitabine doublet also 
noted grade 3 hand-foot syndrome; incidences were similar 
in the combination and single-agent capecitabine arms.20 
Constitutional symptoms (fatigue/asthenia, fever, and neu-
rological symptoms such as neuropathy) were common but 
were primarily of grades 1 or 2 in severity.19,20,22,23
Contraindications and AE 
management strategies
Over 1300 patients with MBC received ixabepilone therapy 
in the trials mentioned above, and while it was well toler-
ated by the majority of patients,19–21 some patients should not 
be treated with ixabepilone (Table 3). Ixabepilone mono-
therapy is contraindicated in patients with a neutrophil count 
below 1500/mm3 or a platelet count below 100,000/mm3. Cancer Management and Research 2009:1 71
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Ixabepilone monotherapy is also not recommended for patients 
with severe hepatic impairment; ie, those whose aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) 
levels exceed 10 times upper limit of normal (ULN), or 
those whose bilirubin levels exceed 3 times ULN. Moreover, 
moderate-to-severe liver dysfunction was associated with an 
increased risk of neutropenia-related death in patients treated 
with ixabepilone in combination with capecitabine.20 As such, 
ixabepilone in combination with capecitabine is contraindicated 
in patients with AST or ALT levels greater than 2.5 times 
ULN or a bilirubin level greater than ULN. In addition, dose 
reductions are recommended for patients with hepatic impair-
ment and elevated AST, ALT, or bilirubin levels (Table 4). 
Furthermore, due to low water solubility, ixabepilone must 
be diluted in Cremophor EL (polyoxyethylated castor oil); 
therefore, ixabepilone therapy is contraindicated in patients with 
a history of severe hypersensitivity reactions to agents containing 
Cremophor EL.17 In the majority of patients, however, AEs asso-
ciated with ixabepilone therapy can be effectively managed by 
dose reductions and supportive management techniques. Dose 
reduction and premedication strategies for the most common 
ixabepilone-related AEs are summarized in Table 5.
Myelosuppression
Myelosuppression, a common AE associated with cytotoxic 
chemotherapy, arises from drug-related disruption of 
bone marrow.24 It commonly manifests as neutropenia, leukopenia, 
anemia, and/or thrombocytopenia. In ixabepilone clinical trials 
of patients with MBC, the most common hematologic AEs were 
neutropenia and leukopenia.19,20,22,23 Most ixabepilone-induced 
neutropenia is short-lived and should not be a major cause of 
ddose reduction or treatment discontinuation.19,20
Diligent monitoring and intervention can prevent neutro-
penia from progressing to a severe grade and reduce the risk 
for infection.25 Patients who are older, have a poor nutritional 
status, or have a history of severe or febrile neutropenia are 
at greater risk for developing neutropenia;26 risk models 
may be useful in predicting those patients at greatest risk 
for developing neutropenia.27 To assess levels of myelosup-
pression, blood counts (including absolute neutrophil counts 
[ANC]) should be monitored weekly during the first two 
cycles of ixabepilone and as needed in subsequent cycles. 
Following the recommended contraindications for ixabepi-
lone treatment, a patient should not begin a new cycle until 
the ANC is at least 1500/mm3 and the platelet count is at 
least 100,000/mm3.17,28
Both neutropenia and leukopenia can be effectively man-
aged with hematopoietic growth factors (eg, filgrastim).24 
At the physician’s discretion, as many as 12% of patients 
in clinical trials receiving ixabepilone monotherapy and 
20% of patients receiving ixabepilone plus capecitabine 
were also administered supportive treatment with growth 
Table 1 Efficacy of ixabepilone in patients with MBC19–21
Study (Reference) Patients Treatment 
protocol
Overall response 
rate – investigator 
(IRRC)
Survival outcomes
Median PFS Median OS
BMS 081  
(Perez et al 2007)19
women with advanced 
breast cancer that had 
been pretreated with 
anthracyclines, taxanes, 
and capecitabine (n = 113)
ixabepilone 40 mg/m2 
(iv) on day 1 of a 
21-day cycle
18.3% (11.5%) 3.1 months (95% Ci 
2.7–4.2 months)
8.6 months (95% Ci 
6.9–11.1 months)
BMS 046
(Thomas et al 2007; 
Hortobagyi et al 
2008)20,21
women with advanced 
breast cancer that had 
been pretreated with 
anthracyclines and were 




40 mg/m2 (iv) on 
day 1 of a 21-day 
cycle + capecitabine 
2000 mg/m2/day (PO) 
on days 1−14 of a 
21-day cycle
42% vs 23% 5.3 vs 3.8 months 
(HR: 0.78; 
95% Ci 0.67−0.91; 
P = 0.0011)
12.9 vs 11.1 months 
(HR: 0.90;  
95% Ci 0.77–1.05; 
P = 0.1936)
BMS 048
Hortobagyi et al 
2008)21
women with advanced 
breast cancer that had 
been pretreated with 





(PO) on days 1−14 of 
a 21-day cycle
43% vs 29% 6.2 vs 4.4 months 
(HR: 0.79; 
95% Ci 0.69–0.90; 
P = 0.0005)
16.4 vs 15.6 months 
(HR: 0.90;  
95% Ci 0.78–1.03; 
P = 0.1162)
Abbreviations: CI, confidence interval; HR, hazard ratio; IRRC, independent radiology review committee; MBC, metastatic breast cancer; n/a, not applicable; OS, overall 
survival; PFS, progression-free survival; PO, per os (by mouth); iv, intravenous.Cancer Management and Research 2009:1 72
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factors (mostly filgrastim) for neutropenia.19,20,22,23 While 
these findings did not warrant a recommendation for pro-
phylactic or routine use of growth factors during ixabepilone 
therapy, they should be considered in patients whose ANC 
drops below 1000/mm3. Under these circumstances, it is 
recommended that ANC be reassessed every 3 days until 
recovery and that the use of growth factors be considered 
with every subsequent cycle of ixabepilone.17 Notably, use 
of these growth factors may exacerbate treatment-related 
arthralgia and myalgia.29
Neuropathy
Neuropathy is a common AE associated with MSAs, including 
the taxanes and epothilones, possibly because microtubule 
stabilization may damage cells within peripheral nerves.30 The 
incidence of peripheral neuropathy varies depending on the drug 
Table 2 incidence of adverse reactions in MBC patients receiving ixabepilone17
BMS 046 BMS 081








Incidence of hematologic adverse events, grade 3 (grade 4)
Neutropenia 32% (36%) 9% (2%) 31% (23%)
Febrile neutropeniaa 5% 1% 3%
Leukopenia 41% (16%) 5% (1%) 36% (13%)
Anemia 8% (2%) 4% (1%) 6% (2%)
Thrombocytopenia 5% (3%) 2% (2%) 5% (2%)
Incidence of nonhematologic adverse events, total (grade 3/4)b
Peripheral neuropathy, 
sensory
65% (21%) 16% (0%) 62% (14%)
Peripheral neuropathy, 
motor
16% (5%) 1% (0%) 10% (1%)
Headachec 8% (1%) 3% (0%) 11% (0%)
Taste disorder 12% (0%) 4% (0%) 6% (0%)
Fatigue/asthenia 60% (16%) 29% (4%) 56% (13%)
Pyrexiac 10% (1%) 4% (0%) 8% (1%)
Myalgia/arthralgiac 39% (8%) 5% (1%) 49% (8%)
Musculoskeletal painc 23% (2%) 5% (0%) 20% (3%)
Nausea 53% (3%) 40% (2%) 42% (2%)
vomiting 39% (4%) 24% (2%) 29% (1%)
Stomatitis/mucositis 31% (4%) 20% (3%) 29% (6%)
Diarrhea 44% (6%) 39% (9%) 22% (1%)
Constipation 22% (0%) 6% (1%) 16% (2%)
Abdominal pain 24% (2%) 14% (1%) 13% (2%)
Anorexiac 34% (3%) 15% (1%) 19% (2%)
weight decreased 11% (0%) 3% (0%) 6% (0%)
Alopecia 31% (0%) 3% (0%) 48% (0%)
Skin rashc 17% (1%) 7% (0%) 9% (2%)
Nail disorderc 24% (2%) 10% (1%) 9% (0%)
Hand-foot syndromec 64% (18%) 63% (17%) 8% (2%)
Skin hyperpigmentation 11% (0%) 14% (0%) 2% (0%)
aNational Cancer institute Common Toxicity Criteria grading for febrile neutropenia ranges from grade 3 to 5.    Three patients (1%) experienced grade 5 (fatal) febrile neutropenia.
bThe following adverse events were reported in 10% of patients: hypersensitivity, edema, pain, chest pain, dyspnea, cough, gastroesophageal reflux disease, pruritus, skin 
exfoliation, upper respiratory infection, febrile neutropenia, dehydration, insomnia, dizziness, increased lacrimation, and hot flush.
cNo grade 4 reports.Cancer Management and Research 2009:1 73
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dose per cycle and the cumulative drug dose, the treatment 
schedule (eg, duration and frequency of administration), and any 
comorbidities such as the presence of diabetes mellitus or other 
endocrine disorders, concurrent administration of neurotoxic 
agents, alcoholism, or advanced age.30–32
The incidence and severity of chemotherapy-induced, 
neuropathy-related AEs in clinical studies is often difficult to 
interpret because of the subjectivity of patient reporting and 
the existence of multiple neuropathy grading scales.33 The 
FDA prefers that AEs be graded with the National Cancer 
Institute’s Common Terminology Criteria for Adverse Events 
(CTCAE) (www.fda.gov), and the most recent ixabepilone 
MBC trials used this system (versions 2 and 3) to grade AEs, 
including neuropathy.19,20,22,23
Peripheral sensory neuropathy was the most common 
serious (grade 3/4) nonhematologic adverse event noted 
during the pivotal clinical trials of ixabepilone as a single 
agent or in combination with capecitabine (Table 2).17 
Following the FDA approval of ixabepilone for marketing in 
the US, data from Studies 081, 046, and 048 were submitted 
to the European Medicines Agency (EMEA) in 2008 to 
gain approval for marketing in the European Union as well. 
In November 2008, however, the Committee for Medicinal 
Products for Human Use (CHMP) expressed a concern that 
the benefits of ixabepilone might not outweigh the risks. 
This negative opinion was based largely on the incidence 
and severity of peripheral neuropathy reported in the clinical 
trials (Table 2).
It is noteworthy that although the women in the 081, 
046, and 048 studies had undergone multiple prior treat-
ments with neurotoxic chemotherapy prior to their entering 
the ixabepilone clinical trials, the incidence of neuropathy 
associated with administering ixabepilone every 21 days 
was similar to incidences observed with administering the 
taxanes every 21 days (Table 2; rates of taxane-induced 
peripheral neuropathy ranged from 2% to 33% with 
Cremophor EL-based paclitaxel, 1% to 9% with docetaxel, 
and 0% to 11% with nanoparticle albumin-bound paclitaxel 
[formulated without Cremophor EL]).30 Also worth noting 
is that although peripheral neuropathy is one of the more 
common and serious AEs associated with ixabepilone 
therapy, it is usually sensory in nature, transient, and 
reversible. Patients with grade 3 or 4 peripheral sensory 
neuropathy in the 048 confirmatory trial, all of whom were 
heavily pretreated with neurotoxic agents, improved to 
baseline in a median time of 6 weeks from onset.34 This AE 
could effectively be managed through dose reduction or 
treatment delay, which allowed patients to remain on study 
and continue to receive treatment.19,20,22,23
As is true with myelosuppression, early recognition of 
symptoms and provision of supportive care can effectively 
prevent severe events.30,35,36 Clinical assessments, including 
physical examinations, are presently the best method to assess 
drug-induced peripheral neuropathy. Baseline analyses of 
motor skills and regular neuropathy assessments will aid 
in identifying at-risk patients and ensure early recognition 
Table 4 Recommended ixabepilone monotherapy dose adjustments for patients with pre-existing hepatic impairment17
Condition Transaminase levels (× ULN) Bilirubin level (× ULN)a Starting doseb (mg/m2)
Mild hepatic impairment AST and ALT  2.5  AND 1.0 40c
AST and ALT  10  AND 1.5 32c
Moderate hepatic impairment AST and ALT  10  AND 1.5 to 3 20–30c
aexcluding patients whose total bilirubin is elevated due to Gilbert’s disease.
bRefers to dose of ixabepilone when used as monotherapy.
cixabepilone in combination with capecitabine is contraindicated in these patients.
Abbreviations: ALT, alanine aminotransferase;   AST, aspartate aminotransferase; ULN, upper limit of normal.
Table 3 Contraindications for ixabepilone therapy17
Ixabepilone therapy is contraindicated in the following situations:
•  Patient has known hypersensitivity to drugs formulated with Cremophor eL
•  Patient has a baseline neutrophil count that is less than 1500 cells/mm3
•  Patient has a platelet count that is less than 100,000 cells/mm3
•  Patient exhibits mild hepatic impairment (combination therapy with capecitabine is contraindicated)
    Patient has aspartate aminotransferase or alanine aminotransferase levels that exceed 2.5 times the upper limit of normal, or
    Patient has bilirubin levels greater than the upper limit of normalCancer Management and Research 2009:1 74
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of symptom onset and progression.17,32,35 Patients should be 
informed of the importance of proactive reporting of their 
neuropathy-associated symptoms (eg, numbness, tingling, 
or burning sensations in the hands or feet) before significant 
progression occurs.32,37 The potential risk of ischemic and 
thermal injuries due to loss of sensation in the extremities 
should also be emphasized.37
Patients with paclitaxel-induced neuropathic pain have 
experienced symptomatic relief with the use of amitrip-
tyline 10 to 50 mg.30 A number of neuroprotective agents 
(eg, glutamine, glutathione, vitamin E, acetyl-l-carnitine, 
calcium, and magnesium) are being investigated for the 
prevention of neurotoxic injury; however, the clinical utility 
of these agents remains largely unknown.36−38 In a clinical 
study designed to assess the neuroprotective effects of glu-
tamine in patients receiving high-dose paclitaxel, glutamine 
was associated with a significant reduction in the severity 
of peripheral neuropathy and had positive effects on toe and 
finger numbness, motor weakness, and vibratory sensation.39 
Additional nonpharmacologic interventions (eg, exercise, 
physical therapy, massage) and the use of suggested self-care 
measures (eg, avoidance of extreme temperatures and other 
stimuli, and regular inspections of feet for injury) may 
enhance patient quality of life and safety.32,35,37
Myalgia and arthralgia
Myalgia and arthralgia are among the most common 
nonhematologic AEs observed during treatment with agents 
that target microtubules, but their etiology and associated 
management techniques are underrepresented in the 
oncology literature compared to other common toxicities.40 
Ixabepilone-associated myalgias and arthralgias are typically 
moderate in severity; while dose reduction is usually not 
necessary for transient myalgia/arthralgia, ongoing events 
may require intervention, and any AE deemed disabling 
warrants treatment discontinuation.17
Risk factors for myalgia and arthralgia are similar to those 
for peripheral neuropathy,29 so patients should be assessed 
for these AEs as well. Myalgia and arthralgia differ from 
neuropathic pain in both presentation and recommended 
treatment, and practitioners should bear this point in mind 
when assessing patients for cancer-related pain. Patients often 
describe myalgias and arthralgias as dull, poorly localized 
aches, the former in large axial muscles, arms, and legs, and 
the latter in limb joints. As mentioned above, arthralgias and 
myalgias may be exacerbated by hematopoietic growth factor 
use, which is itself associated with flulike aches.29
Chemotherapy-related myalgias and arthralgias are thought 
to have an inflammatory component, and agents such as 
nonsteroidal anti-inflammatory drugs (NSAIDs), antihistamines, 
and opiates have proven effective at managing taxane-induced 
arthralgias and myalgias.29 Gabapentin 300 mg administered 
3 times daily (tid) for 2 days before and 5 days after infusion 
has also been shown to reduce taxane-associated myalgia/
arthralgia, while gabapentin 400 mg tid has demonstrated relief 
of paclitaxel-induced severe myalgia.12 Notably, gabapentin 
Table 5 Common ixabepilone-related adverse events and associated management strategies17
Symptom Adverse event Management strategy
Myelosuppression
  Low white blood cell count
 
Neutrophil count 500/mm3 7 d
 
Dose reduction (20%)
  Fever Febrile neutropenia Dose reduction (20%)
    Signs of infection (chills, cough, 
burning, or pain during urination)
Platelet count 25,000/mm3 
or 50,000/mm3 with bleeding
Dose reduction (20%)
Neuropathy
    Numbness, tingling, burning in 
hands or feet
 
Moderate grade 2 neuropathy 7 d 
Severe grade 3 neuropathy 7 d 
Severe grade 3 neuropathy 7 d or 
disabling neuropathy
 
Dose reduction (20%) 
Dose reduction (20%) 
Discontinue treatment
Allergic reactions during infusion
  itching, hives, or rash 
  Flushed face 
    Sudden swelling of the face, throat, 
or tongue
  Tightness in chest, difficulty breathing 
  Faint or feeling of dizziness 
  Heart palpitations
 
All patients (no adverse event)
 
Previous hypersensitivity reaction 




Premedication with H1 and H2 antagonists 
1 h prior to infusion
Premedication with corticosteroids 
(eg, dexamethasone 20 mg iv, 30 min prior 
to infusion or orally, 60 min prior to infusion)
Stop treatment and begin aggressive 
supportive treatment (eg, epinephrine, 
corticosteroids)
Abbreviation: iv, intravenous.Cancer Management and Research 2009:1 75
ixabepilone for taxane-resistant MBC Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
may not be as effective for the treatment of ixabepilone-related 
neuropathic pain,41 emphasizing the importance of accurate 
cancer pain assessment during therapy.
Fatigue
An overwhelming majority of cancer patients experience 
fatigue, and this AE is typically the result of multiple 
underlying causes related to treatment, other comorbidities, 
or the cancer itself.42 Fatigue associated with ixabepilone 
is usually mild to moderate in severity, and dose reduction 
is usually not necessary.17
Use of exercise to manage chemotherapy-related fatigue is 
well supported by studies in cancer patients, and it is currently 
the only intervention rated as “Recommended for Practice” by 
the current Oncology Nursing Society (ONS) fatigue guidelines 
(available at www.ons.org). Although additional research is 
needed to determine which types of exercise are most effec-
tive in which patient populations, it is clear that exercise 
need not be complex or high intensity to be beneficial. The 
appropriate exercises, as well as their intensity and duration, 
should be determined on a case-by-case basis after consider-
ing the patient’s overall level of functionality, comorbidities, 
confounding AEs (eg, myelosuppression that results in low 
white blood cell or platelet counts), and personal preference.42,43 
As with any intervention, exercise routines should be monitored 
carefully throughout the patient’s course of treatment.
At present, insufficient data preclude the recommendation of 
any pharmacological agents for the treatment of chemotherapy-
associated fatigue, and the ONS categorizes pharmacological 
interventions for fatigue under “Effectiveness Not Established.” 
Multiple agents have demonstrated some level of efficacy in 
clinical trials: psychostimulants (eg, methylphenidate and dex-
methylphenidate), antidepressants (eg, paroxetine, bupropion), 
progestational agents, and corticosteroids,42,43 although some 
of these agents carry their own risk of AEs that may outweigh 
the benefits.
Fatigue can stem from or be influenced by other issues 
related to the cancer (autonomic dysfunction, altered hormone, 
or interleukin secretion) or the chemotherapy regimen (anemia, 
pain, sleep disturbance, emotional distress). As such, proactive 
monitoring and management of other treatment-related AEs 
may alleviate or lessen fatigue.42−44
Hypersensitivity reactions
Cremophor EL, used as a diluent for water-insoluble drugs, 
is associated with its own spectrum of AEs, including severe 
anaphylactoid hypersensitivity reactions, hyperlipidemia, 
abnormal lipoprotein patterns, erythrocyte aggregation, and 
peripheral neuropathy.45 Ixabepilone is currently formulated 
with Cremophor EL, although less of this diluent is required 
than is necessary for standard taxane formulations.17,46 Among 
all patients with MBC who received ixabepilone in the clinical 
studies that led to its FDA approval (n = 1323), only nine (1%) 
of these patients had severe hypersensitivity reactions.17,19,20
To prevent severe hypersensitivity reactions to the 
Cremophor vehicle, patients receiving ixabepilone should 
be premedicated with an H1 (eg, diphenhydramine 50 mg 
orally or equivalent) and an H2 (eg, ranitidine 150 to 300 mg 
orally or equivalent) antagonist approximately 1 hour prior to 
infusion (Table 5).17 In contrast to the taxanes, prophylactic 
premedication with steroids is not required for all patients 
receiving ixabepilone. However, patients who have previously 
experienced hypersensitivity reactions during ixabepilone 
therapy require premedication with high-dose corticosteroids 
(eg, dexamethasone 20 mg IV, 30 minutes before infusion 
or orally, 60 minutes before infusion) in addition to pretreat-
ment with H1 and H2 antagonists prior to subsequent dosing 
(Table 5).17 Prolonging the infusion time during treatment 
may further minimize the risk of hypersensitivity reactions. 
If severe hypersensitivity reactions do occur, the ixabepilone 
infusion should be stopped and aggressive supportive treatment 
(eg, epinephrine and corticosteroids) initiated. Patients with a 
history of severe hypersensitivity reactions to agents containing 
Cremophor EL should not be treated with ixabepilone.17
Dosing and administration
Ixabepilone is formulated for IV administration, and the 
recommended dose is 40 mg/m2 infused over 3 hours every 
3 weeks. Dosing in patients with a body surface area of 
greater than 2.2 m2 should be calculated based on a value of 
2.2 m2. Ixabepilone is supplied as a white powder in sterile, 
single-use 15- or 45-mg vials, packaged as a kit with a vial of 
premeasured diluent (52.8% w/v purified polyoxyethylated 
castor oil and 39.8% w/v dehydrated alcohol, USP). For 
optimal stability, ixabepilone is further diluted to its suggested 
final concentration (0.2 to 0.6 mg/mL) with Lactated Ringer’s 
Injection, USP (LRI), normal saline (NS, pH adjusted with 
sodium bicarbonate), or Plasma-Lyte A Injection, pH 7.4, 
prior to administration.17,47 LRI has been used as a diluent 
due to its pH range of 6.0 to 7.5, because the stability of 
ixabepilone has been shown to decrease up to 3-fold in lower 
pH solutions;17 however, the FDA approved the use of these 
two alternative diluents for ixabepilone in 2009.47 When 
using a 250-mL or 500-mL bag of NS (in the form of 0.9% 
Sodium Chloride Injection, USP) to prepare the infusion, the 
pH must be adjusted to between 6.0 and 9.0. To adjust the pH, Cancer Management and Research 2009:1 76
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add 2 molar equivalents (ie, 2 mL of an 8.4% w/v solution 
or 4 mL of a 4.2% w/v solution) of Sodium Bicarbonate 
Injection, USP, prior to adding the constituted ixabepilone 
solution. Importantly, di-(2-ethylhexyl)phthalate (DEHP)-free 
solution bags, infusion containers, and administration sets must 
be used. The final infusion solution is administered using an 
in-line filter with a 0.2 to 1.2 µm microporous membrane within 
6 hours of preparation.
Conclusion
Because of the high rates of tumor resistance observed with 
available chemotherapeutic agents, optimal management 
of MBC is a significant challenge to healthcare profes-
sionals. Ixabepilone, a novel MSA that is structurally and 
pharmacologically distinct from taxanes, was recently 
approved by the FDA as monotherapy or in combination 
with capecitabine for the treatment of resistant MBC. This 
approval was based on the results of several clinical studies 
that demonstrated a manageable safety profile and substantial 
antitumor activity of ixabepilone in patients with treatment-
resistant MBC. Clinical studies evaluating ixabepilone for the 
treatment of other cancer types are ongoing and, in some cases, 
suggest promising antitumor activity. As such, healthcare 
professionals will most likely encounter an increasing number 
of patients who may be candidates for ixabepilone therapy.
Treatment-related AEs were similar to those observed 
with many other chemotherapeutic agents and included 
primarily hematologic toxicity (eg, neutropenia and leukopenia) 
and sensory neuropathy. Ixabepilone-related AEs were 
predictable and were managed with dose modification or 
delay. Importantly, proactive intervention and patient edu-
cation can aid in identifying ixabepilone-associated AEs 
before they progress to severe events. As a result, healthcare 
providers can intervene with dose modification and other 
interventions, increasing the likelihood that patients will 
remain on treatment for a longer period of time without 
significantly disrupting their overall quality of life. The 
introduction of ixabepilone to the armamentarium of MBC 
treatment options represents an exciting new era for patients, 
particularly those with taxane-resistant MBC who currently 
have few treatment options.
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